Medical Research
Drink HRW Reports on Start of Large-Scale Randomized Controlled Trial and Preliminary Findings from Pilot Trial on the Reduction in Complications from COVID-19
COQUITLAM, BC, Canada — Drink HRW is excited to announce that a large, double-blind placebo-controlled trial is set to begin this week in France, initiated by the University of Grenoble-Alpes. At the request of the researchers, Drink HRW is supplying the hydrogen tablets for the study as well as a donation to improve the size and scope of the research. It has no other involvement in the research or the decision to publish results….
C Diff Foundation Hosts Live-Online Symposium for Patients, Families and Caregivers
TAMPA, Fla. — The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, Jan. 15 from 1 to 4 p.m. EST. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection in addition to those who are recovering or who have experienced recurrences. The patients, family members and caregivers will all benefit from the information and up-to-date data presented….
The C Diff Foundation Assures Patients C. diff. Clinical Trials Continue to Move Forward Safely
TAMPA, Fla. — While some patients diagnosed with Clostridioides difficile (C. diff., C. difficile, CDI) believe they have run into clinical trial roadblocks, due to the recent focus on the pandemic, the C Diff Foundation wants them to know they are not out of options. Safe and active clinical trials continue….
Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act Funded Program
AUSTIN, Texas — Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform….
2020 International Clostridioides difficile (C. diff., C. difficile) Virtual Conference and Health EXPO Nov. 14
TAMPA, Fla. — C Diff Foundation announced today that the 8th Annual International C. diff. Virtual-Online Conference and Health EXPO will be a 5-1/2 hour online program with over fourteen international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies….
Progenabiome Shares New Data on Fecal Transplant, Sars-Cov-2 at ACG 2020
VENTURA, Calif. — The American College of Gastroenterology (ACG) named Progenabiome “Outstanding Poster Presenter” for its poster: “Successful Bacterial Engraftment Identified by Next Generation Sequencing Following Fecal Microbiota Transplantation for Clostridioides difficile Infection,” which will be presented virtually at the ACG Annual Scientific Meeting this week….
Alzheimer’s Patient Recalls Daughter’s Birthday After Undergoing Fecal Transplant
VENTURA, Calif. — Dr. Sabine Hazan, founder of ProgenaBiome, a genetic sequencing lab in California, achieved rapid improvement in Alzheimer’s disease (AD) symptoms in an 82-year-old male patient following fecal microbiota transplantation (FMT)….
NED Biosystems Announces Leading Infectious Disease Research Scientist Michael Mansour, MD, PhD To Serve as Medical Advisor
CAMBRIDGE, Mass. — NED Biosystems, an innovative clinical-stage biotech company developing therapies for cancer and the novel coronavirus, is pleased to announce that Michael Mansour, MD, PhD, will serve as the Company’s Medical Advisor of Infectious Disease….
Leading Experts in Cancer Research Nabeel El-Bardeesy and Razelle Kurzrock Join NED Biosystems’ Scientific Advisory Board
CAMBRIDGE, Mass. — NED Biosystems, an innovative clinical-stage biotech company developing oral therapies for cancer and novel coronavirus, is pleased to announce that Nabeel El-Bardeesy, PhD and Razelle Kurzrock, MD have joined the Company’s Scientific Advisory Board….
Zeblok Computational Announces Partnership with Laufer Center and CEWIT – COVID-19 Drug Discovery
STONY BROOK, N.Y. — Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok’s secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster….